<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To elucidate the mechanism of vascular <z:mp ids='MP_0005048'>thrombosis</z:mp> in patients with <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> and the <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> changes in factors associated with haemostasis were investigated </plain></SENT>
<SENT sid="1" pm="."><plain>The <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> was associated with an increased incidence of <z:mp ids='MP_0005048'>thrombosis</z:mp>, particularly <z:hpo ids='HP_0005305'>cerebral thrombosis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Concentrations of fibrinopeptide A and fibrinopeptide B beta 15-42 were significantly raised in the plasma of patients with <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> and the <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> compared with concentrations in patients without the <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>The tendency towards formation of <z:mp ids='MP_0005048'>thrombosis</z:mp> was not found in <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> patients with the <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>, however </plain></SENT>
<SENT sid="4" pm="."><plain>Concentrations of <z:chebi fb="0" ids="28728">thromboxane B2</z:chebi> were remarkably raised in the plasma of the two patients with the <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> who had recently had <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>Concentrations of 6-keto-<z:chebi fb="0" ids="28852">prostaglandin F1 alpha</z:chebi>, protein C, antithrombin III, and plasminogen were similar in both groups </plain></SENT>
<SENT sid="6" pm="."><plain>No significant decrease in serum stimulatory activity on prostacyclin production by cultured aortic endothelial cells was noted in <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> patients with the <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>, but inhibition was present in the two patients with recent <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>These results indicate that although patients with the <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> are not always in a <z:e sem="disease" ids="C0398623" disease_type="Disease or Syndrome" abbrv="">hypercoagulable state</z:e>, haemostatic abnormalities found in some patients with the <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> may be predictive of thrombotic events </plain></SENT>
</text></document>